However, our survey of three distinct cohorts of TNBC cases establishes a baseline prevalence (14%) for PDJ + in this aggressive subtype, includes scoring of single cells within each tumor, and provides preliminary correlative association with increased TILs, a signature associated with improved responses to ICI therapies. This evidence concerns the gene PRKN and neoplasm.